

Ref: 69/SE/LC/2024-25

Date: 12/11/2024

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051
Scrip Symbol: ENTERO

Scrip Code: 544122

Dear Sir/Madam,

Subject: Submission of Unaudited Financial Results for quarter and half year ended on September 30, 2024.

Reference: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("LODR")

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today i.e., November 12, 2024, inter alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024 and Limited Review Report on the aforesaid Unaudited Financial Results.

The said results in the prescribed format along with Limited Review Report of Statutory Auditors of the Company are enclosed herewith.

The aforesaid Unaudited Financial Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

The Board Meeting commenced at 2:00 PM (IST) and concluded at 6:20 PM (IST).

This outcome and results will also be uploaded on the website of the Company.

You are requested to take the same on record.

For Entero Healthcare Solutions Limited

Jayant Prakash
General Counsel, Company Secretary & Compliance Officer
(Mem: F6742)



Entero Healthcare Solutions Limited
(formerly known as Entero Healthcare Solutions Private Limited)
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051
CIN: L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30 September 2024

(Rs. in Millions, except per equity share data)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 24 (Unaudited)	30 June 24 (Unaudited)	30 September 23 (Unaudited) (Refer Note 3)	30 September 2024 (Unaudited)	30 September 2023 (Unaudited) (Refer Note 3)	31 March 2024 (Audited)
1	Income						
	a) Revenue from operations	1,128.32	1,223.84	738.14	2,352.16	1,350.14	3,181.61
	b) Other Income	288.14	321.71	165.19	609.85	312.80	899.25
	Total Income	1,416.46	1,545.55	903.33	2,962.01	1,662.94	4,080.86
2	Expenses						
	a) Purchase of Stock-in-trade	1,001.07	1,273.35	621.29	2,274.42	1,160.79	2,885.03
	b) Changes in Inventories of Stock-in-trade	(7.86)	(227.87)	3.73	(235.73)	(31.37)	(189.65)
	c) Employee benefits expense	129.50	114.89	147.18	244.39	283.05	562.46
	d) Finance costs	3.91	4.10	73.23	8.01	119.74	223.18
	e) Depreciation and amortisation expense	21.29	21.69	22.94	42.98	47.00	87.48
	f) Other expenses	66.36	81.96	57.82	148.32	105.73	268.71
	Total Expenses	1,214.27	1,268.12	926.19	2,482.39	1,684.94	3,837.21
3	Profit/(Loss) before tax (1) - (2)	202.19	277.43	(22.86)	479.62	(22.00)	243.65
4	Tax expenses						
	Current tax	19.72	38.22	-	57.94	-	-
	Deferred tax charge/(credit)	29.18	30.46	(1.42)	59.64	(24.16)	(140.75)
	Total tax expenses	48.90	68.68	(1.42)	117.58	(24.16)	(140.75)
5	Profit/(loss) for the period/year (3) - (4)	153.28	208.75	(21.44)	362.04	2.16	384.40
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss	(0.98)	0.35	0.70	(0.63)	0.70	1.40
	Income tax effect on above	0.25	(0.09)	-	0.16	-	(0.35)
	Total other comprehensive income	(0.73)	0.26	0.70	(0.47)	0.70	1.05
7	Total comprehensive income (5) + (6)	152.55	209.01	(20.74)	361.57	2.86	385.45
8	Paid-up equity share capital (face value - Rs. 10 per share)	434.94	434.94	160.67	434.94	160.67	434.94
9	Other equity						15,829.19
10	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	3.52	4.80	(0.62)	8.32	0.06	10.63
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	3.52	4.80	(0.62)	8.31	0.06	10.63

(*not annualised for the quarter and half year)

See accompanying notes to the audited standalone financial results





Entero Healthcare Solutions Limited
(formerly known as Entero Healthcare Solutions Private Limited)
Registered Office: Plot No. I-35, Building-B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051
CIN: L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

NOTES:

- The unaudited standalone financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited standalone financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 12 November 2024. These unaudited financial results have been subjected to limited review by the statutory auditors of the Company and they have expressed an unmodified conclusion on these unaudited standalone financial results.
- The Company operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Company has only one reportable segment as per Ind AS 108 "Operating Segments".
- The Equity shares of the Company were listed on the BSE Limited ("BSE") and National Stock Exchanges of India Limited ("NSE") on 16 February 2024. Consequently, the requirement for submission of quarterly financial results to the stock exchanges became applicable to the Company with effect from quarter ended 31 December 2023. Hence, the Company was not required to present and prepare financial results for the quarter and half year ended 30 September 2023, which has been prepared by the Company management.
- The utilization of the proceeds (net of IPO expenses) as on 30 September 2024 is summarized as below:

Particulars	Utilisation as per prospectus	Utilisation up to 30 September 2024	Unutilised up to 30 September 2024
Repayment/prepayment in full or part, of certain borrowings availed of by our company	1,425.00	1,425.00	-
Funding of long term working capital requirements of the company and its subsidiaries	4,800.00	2,964.50	1,835.50
Inorganic growth initiative through acquisitions	2,370.00	1,930.00	440.00
General corporate purposes	918.30	355.80	562.50
Total	9,513.30	6,675.30	2,838.00

- During the period ended 30 September 2024, the Company has entered into share purchase agreements with the following entities, resulting in these entities becoming the subsidiary of the Company.

Name of the entity	Date of share transfer	Number of shares acquired	% of shareholding
Avenir Lifecare Pharma Private Limited	07-May-24	8,000	80%
Suprabhat Pharmaceutical Distributors Private Limited	12-Jun-24	10,000	100%
Devi Pharma Wellness Private Limited	14-Jul-24	10,000	100%
Gourav Medical Agencies Private Limited	09-Aug-24	8,000	80%
Srinivasa Lifecare Private Limited	13-Aug-24	7,000	70%
Peerless Biotech Private Limited	16-Aug-24	30,000	60%
Sai Pharma Distributors Private Limited	16-Aug-24	6,93,000	70%

- Subsequent to the quarter and half year ended 30 September 2024, the Company has entered into share purchase agreement with Ujjain Maheshwari Pharma Distributors Private Limited for purchase of 10,000 equity shares at Rs. 10 each (100% stake), resulting in the entity becoming the subsidiary of the Company. The date of share transfer is 29 October 2024.
- The above unaudited standalone financial results of the Company are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE (www.bseindia.com).
- Previous year's/period's figures have been regrouped/reclassified wherever necessary to conform to current period's classification.

Entero Healthcare Solutions Limited

Prabhat Agrawal
CEO & Managing Director
DIN: 07466382
Place: Mumbai
Date: 12 November 2024





Entero Healthcare Solutions Limited
(formerly known as Entero Healthcare Solutions Private Limited)
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051
CIN: L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Standalone Balance Sheet as at 30 September 2024
(Amount in Millions, unless otherwise stated)

Particulars	30 September 24 (Unaudited)	31 March 2024 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	161.42	171.90
Right to use assets	119.48	138.73
Other Intangible assets	32.03	33.80
Financial assets		
Investments in subsidiaries		
Other financial assets	2,281.78	405.38
Non current tax assets (net)	58.68	109.26
Deferred tax asset (net)	80.92	76.51
Deferred tax asset (net)	106.19	140.40
Total non-current assets	2,840.50	1,076.98
Current assets		
Inventories	713.79	478.06
Financial assets		
Trade receivables		
Cash and cash equivalents	1,068.95	1,131.86
Bank balances other than cash and cash equivalent	386.62	933.39
Loans	3,361.65	6,990.13
Other financial assets	7,905.21	5,891.69
Other current assets	1,381.85	934.23
Total current assets	187.68	250.49
TOTAL ASSETS	15,005.75	16,609.85
	17,846.25	17,685.83
EQUITY AND LIABILITIES		
Equity		
Equity share capital	434.94	434.94
Other equity	16,202.14	15,829.19
Total equity	16,637.08	16,264.13
Liabilities		
Non-current liabilities		
Financial liabilities		
Lease liabilities		
Provisions	109.78	129.51
Total non-current liabilities	32.70	13.95
	142.46	143.46
Current liabilities		
Financial liabilities		
Lease liabilities		
Trade payables	46.50	46.88
i) total outstanding dues of micro enterprises and small enterprises		
ii) total outstanding dues of creditors other than micro enterprise and small enterprise	0.72	4.82
Other financial liabilities	638.01	644.17
Other current liabilities	333.13	506.65
Provisions	42.39	59.24
Total current liabilities	5.96	16.48
TOTAL LIABILITIES	1,066.71	1,278.24
TOTAL EQUITY AND LIABILITIES	1,209.17	1,421.70
	17,846.25	17,685.83





Entero Healthcare Solutions Limited
(formerly known as Entero Healthcare Solutions Private Limited)
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kuria Complex, Mumbai - 400051
CIN: L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Standalone statement of cash flows for the half year ended 30 September 2024
(Amount in Millions, unless otherwise stated)

Particulars	For half year ended 30 September 2024 (Unaudited)	For half year ended 30 September 2023 (Unaudited)
Cash flow from operating activities		
Profit / (Loss) before tax	479.62	(22.00)
Adjustments for:		
Depreciation and amortization expense	42.98	47.03
Finance costs	8.01	119.74
Interest income	(554.20)	(310.22)
Provision for expected credit loss	11.20	(8.79)
Profit on sale of property, plant and equipment	(0.17)	-
Commission income on corporate guarantee	(14.49)	-
Gain on termination of lease	(2.23)	-
Employee stock option expenses	11.39	2.04
Provision for sales return	-	(14.90)
	(17.89)	(187.10)
Changes in working capital		
(Increase)/decrease in inventories	(235.73)	(31.37)
(Increase)/decrease in trade receivables	51.72	(357.59)
(Increase)/decrease in other financial assets	(354.28)	(71.77)
(Increase)/decrease in other current assets	62.80	(96.99)
Increase/ (decrease) in trade payables	(10.27)	50.94
Increase/ (decrease) in other financial liabilities	(18.22)	13.66
Increase/ (decrease) in other current liabilities	(16.85)	9.23
Increase/ (decrease) in provisions and employee benefits	7.60	6.27
Cash generated from/(used) in operations	(531.12)	(664.72)
Income tax paid (net)	(87.62)	(1.74)
Net cash flows generated from/(used) in operating activities (A)	(618.74)	(666.46)
Cash flow from investing activities		
Investment in subsidiaries	(1,683.40)	(0.10)
Loans given to related party	(2,013.52)	(592.41)
Purchase of property, plant and equipment, including movement in CWIP and capital advances	(9.29)	(4.73)
Proceeds from sale of property, plant and equipment	0.65	-
(Increase) / Decrease in fixed deposits with banks having maturity more than three months	3,679.10	168.61
Commission income on corporate guarantee	14.49	-
Interest received	460.80	310.22
Net cash flow generated from/(used) in investing activities (B)	448.83	(118.41)
Cash flow from financing activities		
Proceeds from issue of compulsory convertible preference shares	-	509.84
Share issue expenses	(348.29)	-
Proceeds from long term borrowings	-	620.59
Payment of lease liabilities	(20.56)	(28.83)
Finance costs paid	(8.01)	(109.99)
Net cash generated from/(used in) in financing activities (C)	(376.86)	991.61
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(546.77)	206.74
Cash and cash equivalents at the beginning of the period	933.39	61.15
Cash and cash equivalents at the end of the period	386.62	267.89

NOTES:

- The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard (Ind AS) 7, Statement of Cash Flows as specified in the Companies (Indian Accounting Standards), Rules, 2015 (as amended).
- Cash and cash equivalents comprise:

Particulars	As at 30 September 2024	As at 30 September 2023
Balances with banks		
On current accounts	313.93	217.72
Fixed deposits with maturity of less than 3 months	72.50	50.04
Cash on hand	0.19	0.13
Total cash and cash equivalents at end of the period	386.62	267.89



Independent Auditor's Review Report on Standalone unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) (hereinafter referred to as 'the Company') for the quarter ended September 30, 2024 and the year to date results for the period from April 1, 2024 to September 30, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. The Statement includes results for the quarter ended September 30, 2023, that have been approved by the Board of Directors, and have not been subjected to review or audit by us or another auditor.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Amrish Vaidya
Partner

Membership No.:101739

UDIN: 24101739BKEZWP3174



Place: Mumbai

Date: November 12, 2024



Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN:L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

Statement of Unaudited Consolidated Financial Results for the quarter and half year ended 30 September 2024

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 24 (Unaudited)	30 June 24 (Unaudited)	30 September 23 (Unaudited) (Refer Note 3)	30 September 24 (Unaudited)	30 September 23 (Unaudited) (Refer Note 3)	31 March 2024 (Audited)
1	Income						
	a) Revenue from operations	13,006.92	10,970.36	9,963.04	23,977.28	18,955.01	39,223.10
	b) Other Income	112.79	134.36	20.78	247.15	34.76	144.13
	Total Income	13,119.71	11,104.72	9,983.82	24,224.43	18,989.77	39,367.23
2	Expenses						
	a) Purchase of Stock-in-trade	11,983.59	10,696.72	9,290.55	22,680.31	17,600.30	36,278.08
	b) Changes in inventories of Stock-in-trade	(198.32)	(726.04)	(224.16)	(924.36)	(336.86)	(574.55)
	c) Employee benefits expense	500.66	435.67	372.94	936.33	733.26	1,511.46
	d) Finance costs	114.58	97.04	179.01	211.62	322.91	656.84
	e) Depreciation and amortisation expense	74.94	66.06	59.32	141.00	118.79	250.17
	f) Other expenses	296.50	262.28	238.00	558.78	414.85	889.68
	Total Expenses	12,771.95	10,831.73	9,915.66	23,603.68	18,853.05	39,011.68
3	Profit before tax (1) - (2)	347.76	272.99	68.16	620.75	136.72	355.55
4	Tax expenses						
	Current tax (including tax expense of earlier year)	72.59	61.56	37.82	134.15	66.93	133.78
	Deferred tax charge/(credit)	14.84	6.13	(21.79)	20.97	(46.63)	(176.22)
	Total tax expenses	87.43	67.69	16.03	155.12	20.30	(42.44)
5	Profit for the period (3) - (4)	260.33	205.30	52.13	465.63	116.42	397.99
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss	(0.43)	(0.47)	0.43	(0.90)	0.42	(2.58)
	Income tax effect on above	0.11	0.12	0.15	0.23	0.15	0.41
	Total other comprehensive income	(0.32)	(0.35)	0.58	(0.67)	0.57	(2.17)
7	Total comprehensive income (5) + (6)	260.01	204.95	52.71	464.96	116.99	395.82
8	Profit attributable to:						
	Owners of the Company	236.15	200.80	51.25	436.95	113.65	391.09
	Non-controlling interests	24.18	4.50	0.88	28.68	2.77	6.90
9	Other comprehensive income attributable to:						
	Owners of the Company	(0.32)	(0.35)	0.55	(0.67)	0.55	(2.17)
	Non-controlling interests	0.00	-	0.03	0.00	0.02	(0.00)
10	Total comprehensive income attributable to:						
	Owners of the Company	235.83	200.45	51.80	436.28	114.20	388.92
	Non-controlling interests	24.18	4.50	0.91	28.68	2.79	6.90
11	Paid-up equity share capital (face value - Rs. 10 per share)	434.94	434.94	160.67	434.94	160.67	434.94
12	Other equity						15,945.62
13	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	5.43	4.62	1.49	10.05	2.95	10.81
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	5.42	4.62	1.49	10.03	2.95	10.81

(*not annualised for the quarter and half year)

See accompanying notes to the unaudited consolidated financial results





Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN: L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

NOTES:

- The unaudited consolidated financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited consolidated financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) ("the Holding Company" or "the Company"), and its subsidiaries (the Holding Company along with subsidiaries together referred to as "the Group") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 12 November 2024. These unaudited consolidated financial results have been subjected to limited review by the statutory auditors of the Company and they have expressed an unmodified conclusion on these unaudited consolidated financial results.
- The Group operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Group has only one reportable segment as per Ind AS 108 "Operating Segments".
- The Equity shares of the Holding Company were listed on the BSE Limited ("BSE") and National Stock Exchanges of India Limited ("NSE") on 16 February 2024. Consequently, the requirement for submission of quarterly financial results to the stock exchanges became applicable to the Holding Company with effect from quarter ended 31 December 2023. Hence, the Holding Company was not required to present and prepare quarterly financial results for the quarter and half year ended 30 September 2023, which has been prepared by the Holding Company management.

- The utilization of the proceeds (net of IPO expenses) as on 30 September 2024 is summarized as below:

Particulars	Utilisation as per prospectus	Utilisation up to 30 September 2024	Unutilised up to 30 September 2024
Repayment/prepayment in full or part, of certain borrowings availed by Company	1,425.00	1,425.00	-
Funding of long term working capital requirements of the Company and its subsidiaries	4,800.00	2,964.50	1,835.50
Inorganic growth initiative through acquisitions	2,370.00	1,930.00	440.00
General corporate purposes	918.30	355.80	562.50
Total	9,513.30	6,675.30	2,838.00

- During the quarter ended 30 September 2024, Chhabra Healthcare Solutions Private Limited, a subsidiary of the Company, entered into a business transfer agreement with Amar Drugs Distributors for acquisition of 100% business undertaking on slump sale basis on 9 September 2024. The Company has accounted this acquisition as per Ind AS 103- 'Business Combinations', on provisional basis in the consolidated financial results. The figures for the quarter and six months ended 30 September 2024 include figures of the aforesaid acquired entity from the date of agreement, and are not comparable with the corresponding/ comparative period.

- During the period ended 30 September 2024, the Holding Company has entered into share purchase agreements with the following entities, resulting in these entities becoming the subsidiary of the Holding Company. The Company has accounted these acquisitions as per Ind AS 103- 'Business Combinations', on provisional basis in the consolidated financial results. The figures for the quarter and six months ended 30 September 2024 include figures of the aforesaid acquired entities from the date of share transfer as mentioned below, and are not comparable with the corresponding/ comparative period.

Name of the entity	Date of share transfer	Number of shares acquired	% of shareholding
Avenir Lifecare Pharma Private Limited	07-May-24	8,000	80%
Suprabhat Pharmaceutical Distributors Private Limited	12-Jun-24	10,000	100%
Devil Pharma Wellness Private Limited	14-July-2024	10,000	100%
Gourav Medical Agencies Private Limited	09-August-2024	8,000	80%
Srinivasa Lifecare Private Limited	13-August-2024	7,000	70%
Peerless Biotech Private Limited	16-August-2024	30,000	60%
Sai Pharma Distributors Private Limited	16-August-2024	6,93,000	70%

- Subsequent to the quarter and half year ended 30 September 2024, the Company has entered into share purchase agreement with Ujjain Maheshwari Pharma Distributors Private Limited for purchase of 10,000 equity shares at Rs. 10 each, resulting in the entity becoming 100% subsidiary of the Holding Company. The date of share transfer is 29 October 2024.

- The above unaudited consolidated financial results of the Group are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE(www.bseindia.com).

- Previous year's/period's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's classification.

Entero Healthcare Solutions Limited

Prabhat Agrawal
CEO & Managing Director
DIN: 07466382
Place: Mumbai
Date: 12 November 2024





Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN: L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

Consolidated Balance Sheet as at 30 September 2024

(Amount in million, unless otherwise stated)

Particulars	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	563.57	410.44
Right to Use Asset	779.50	520.41
Goodwill	4,161.51	1,928.16
Other intangible assets	32.97	34.36
Financial assets		
Other Financial Assets	288.05	157.20
Deferred tax asset (net)	183.56	190.26
Non Current tax assets (net)	190.63	99.17
Total non-current assets	6,179.79	3,340.00
Current assets		
Inventories	5,987.01	4,211.55
Financial assets		
Investments	31.93	-
Trade receivables	8,792.40	6,154.04
Cash and cash equivalents	806.45	1,478.46
Bank balances other than cash and cash equivalent	3,699.90	7,455.38
Loans	14.70	0.69
Other financial assets	490.97	258.28
Other current assets	525.85	553.35
Total current assets	20,349.21	20,109.75
TOTAL ASSETS	26,529.00	23,449.75
EQUITY AND LIABILITIES		
Equity		
Equity share capital	434.94	434.94
Other equity	16,393.30	15,945.62
Equity attributable to owners of the company	16,828.24	16,380.56
Non-Controlling Interests	397.65	33.28
Total equity	17,225.89	16,413.84
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	1.12	455.41
Lease Liabilities	701.02	489.69
Provisions	108.44	71.11
Deferred tax Liabilities (net)	2.90	0.26
Total non-current liabilities	813.48	1,016.47
Current liabilities		
Financial liabilities		
Borrowings	2,727.71	2,300.11
Lease Liabilities	181.59	134.53
Trade payables		
i) total outstanding dues of micro enterprises and small enterprises	82.19	184.63
ii) total outstanding dues of creditors other than micro enterprise and small enterprise	3,710.69	2,114.51
Other financial liabilities	1,537.34	1,057.25
Other current liabilities	100.63	158.64
Provisions	23.01	29.36
Current tax liabilities (net)	126.47	40.41
Total current liabilities	8,489.63	6,019.44
TOTAL LIABILITIES	9,303.11	7,035.91
TOTAL EQUITY AND LIABILITIES	26,529.00	23,449.75





Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. 1-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN: L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

Consolidated Statement of Cash Flows for half year ended 30 September 2024

(Amount in million, unless otherwise stated)

Particulars	For half year ended 30 September 2024	For half year ended 30 September 2023
Cash flow from operating activities		
Profit / (loss) before tax	620.75	136.72
Adjustments for:		
Depreciation and amortization expense	141.00	118.79
Finance costs	211.62	322.91
Provision for expected credit loss	57.73	27.40
(Profit)/Loss on sale of property, plant and equipment (net)	0.97	-
Interest income	(235.87)	(30.85)
Provision for sales return	-	(20.57)
Employee stock option expenses	11.39	2.04
	807.59	556.44
Changes in working capital		
(Increase) / Decrease in inventories	(919.86)	(344.33)
(Increase) / Decrease in loans	(14.00)	4.85
(Increase) / Decrease in trade receivables	(1,645.88)	(981.47)
(Increase) / Decrease in other financial assets	(306.79)	(58.95)
(Increase) / Decrease in other current assets	48.72	(69.07)
Increase / (Decrease) in trade payables	927.25	22.71
Increase / (Decrease) in other current liabilities	(135.82)	(44.21)
Increase / (Decrease) in other financial liabilities	151.92	121.14
Increase / (Decrease) in provisions and employee benefits	(23.36)	14.28
Cash used in operations	(1,110.03)	(778.61)
Income tax paid	(140.82)	(48.60)
Net cash flow generated from/ (used in) operating activities (A)	(1,250.85)	(827.21)
Cash flow from investing activities		
Purchase consideration paid towards acquisitions of business	(2,770.82)	(232.74)
Purchase of property, plant and equipment, intangible including movement in CWIP and capital advances	(46.00)	(17.41)
Purchases of investments	(21.51)	-
Proceeds from sale of property, plant and equipment	3.41	-
Interest received	247.48	30.84
(Increase) / Decrease in fixed deposits with bank having maturity more than three months	3,744.12	30.50
Net cash generated from/(used in) investing activities (B)	1,156.68	(188.81)
Cash flow from financing activities		
Proceeds from issue of compulsory convertible preference shares	-	509.85
Share issue expenses	(348.29)	-
Proceeds from long-term borrowings	-	1,284.72
(Repayment) of long-term borrowings	(455.41)	(458.72)
Proceeds/(Repayment) of short-term borrowings (net)	413.13	327.53
Payment of lease liabilities	(96.24)	(96.83)
Finance costs paid	(212.62)	(295.64)
Net cash generated from/(used in) financing activities (C)	(699.43)	1,270.91
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(793.60)	254.89
Cash and cash equivalents at the beginning of the period	1,476.46	253.62
Add : on acquisition of business	123.59	10.78
Cash and cash equivalents at the end of the period	806.45	519.29

NOTES:

1 The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard (Ind AS) 7, Statement of Cash Flows as specified in the Companies (Indian Accounting Standards), Rules, 2015 (as amended).

2 Cash and cash equivalents comprise:

Particulars	As at 30 September 2024	As at 31 March 2024
Balances with banks		
On current accounts	709.42	370.43
Fixed deposits with maturity of less than 3 months	72.50	106.27
Cash on hand	23.19	27.80
Cheques on hand	1.34	14.80
Total cash and cash equivalents at end of the period	806.45	519.29



Independent Auditor's Review Report on consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) (hereinafter referred to as 'the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2024 and the year to-date results for the period from April 1, 2024 to September 30, 2024 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.
4. This Statement includes the results of the Holding Company and the entities listed in Annexure 1.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. We did not review the interim financial results of 6 subsidiaries included in the Statement, whose interim financial results (before consolidation adjustments) reflects total assets of Rs. 3,224.76 millions as at September 30, 2024 and total revenues of Rs. 1 610.13 millions and Rs.3 143.66 millions, total net profit/(loss) after tax of Rs.5.92 millions and Rs. (3.92) millions and total comprehensive income /(loss) of Rs.5.59 millions and Rs. (4.25) millions, for the quarter ended September 30, 2024 and for the period from April 1, 2024 to September 30, 2024, respectively, and net cash outflows of Rs. 48.07 millions for the period from April 1, 2024 to September 30, 2024, as considered in the Statement. These interim financial results has been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. The Statement includes the interim financial results of 22 subsidiaries which have not been reviewed by their auditors and are not subject to review and have been certified by the Holding Company's management, whose interim financial results (before consolidation adjustments) reflects total assets of Rs. 5,047.39 millions as at September 30, 2024 and total revenue of Rs. 2,209.63 millions and Rs.3,086.73 millions, total net profit after tax of Rs. 52.28 millions and Rs. 31.02 millions and total comprehensive income of Rs.52.09 and Rs. 30.83 millions for the quarter ended September 30, 2024 and for the period from April 1, 2024 to September 30, 2024, respectively, and net cash inflows of Rs. 150.43 millions for the period from April 1, 2024 to September 30, 2024, as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.


Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.



8. The Statement includes results for the quarter ended September 30, 2023, that have been approved by the Holding Company's Board of Directors, and have not been subjected to review or audit by us or another auditor.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Amrish Vaidya
Partner

Membership No.:101739

UDIN: 24101739BKEZWQ2633



Place: Mumbai

Date: November 12, 2024

Annexure I to the Independent Auditor's Review Report on consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Novacare Healthcare Solutions Private Limited	Subsidiary
2	R S M Pharma Private Limited	Subsidiary
3	Avenues Pharma Distributors Private Limited	Subsidiary
4	Chirag Medicare Solutions Private Limited	Subsidiary
5	Chethana Pharma Private Limited	Subsidiary
6	Jaggi Enterprises Private Limited	Subsidiary
7	Vasavi Medicare Solutions Private Limited	Subsidiary
8	SYMED Solutions Private Limited	Subsidiary
9	Millennium Medisolutions Private Limited	Subsidiary
10	G.S. Pharmaceutical Distributors Private Limited	Subsidiary
11	Getwell Medicare Solutions Private Limited	Subsidiary
12	Galaxystar Pharma Distributors Private Limited	Subsidiary
13	Barros Enterprises Private Limited	Subsidiary
14	Sesha Balajee Medisolutions Private Limited	Subsidiary
15	Rada Medisolutions Private Limited	Subsidiary
16	Sri Parshva Pharma Distributors Private Limited	Subsidiary
17	Sri Rama Pharmaceutical Distributors Private Limited	Subsidiary
18	Western Healthcare Solutions Private Limited	Subsidiary
19	Chhabra Healthcare Solutions Private Limited	Subsidiary
20	Chethana Healthcare Solutions Private Limited	Subsidiary
21	S.S. Pharma Traders Private Limited	Subsidiary
22	Sundarlal Pharma Distributors Private Limited	Subsidiary
23	New Siva Agencies Private Limited	Subsidiary
24	Saurashtra Medisolutions Private Limited	Subsidiary
25	New RRPD Private Limited	Subsidiary
26	Sree Venkateshwara Medisolutions Private Limited	Subsidiary
27	SVS Lifesciences Private Limited	Subsidiary
28	Swami Medisolutions Private Limited	Subsidiary
29	Atreja Healthcare Solutions Private Limited	Subsidiary
30	CPD Pharma Private Limited	Subsidiary
31	Calcutta Medisolutions Private Limited	Subsidiary
32	Chethana Pharma Distributors Private Limited	Subsidiary
33	City Pharma Distributors Private Limited	Subsidiary
34	Curever Pharma Private Limited	Subsidiary
35	Rimedio Pharma Private Limited	Subsidiary
36	Quomed Life Sciences Private Limited	Subsidiary
37	Zennx Software Solutions Private Limited	Subsidiary
38	Entero R.S. Enterprises Private Limited (w.e.f. September 16, 2023)	Subsidiary
39	Dhanvanthri Super Speciality Private Limited (w.e.f.	Subsidiary



	December 11, 2023)	
40	Avenir Lifecare Pharma Private Limited (w.e.f. May 7, 2024)	Subsidiary
41	Suprabhat Pharmaceuticals Private Limited (w.e.f. June 12, 2024)	Subsidiary
42	Devi Pharma Wellness Private Limited (w.e.f. July 14, 2024)	Subsidiary
43	Gourav Medical Agencies Private Limited (w.e.f. August 9, 2024)	Subsidiary
44	Srinivasa Lifecare Private Limited (w.e.f. August 13, 2024)	Subsidiary
45	Sai Pharma Distributor Private Limited (w.e.f. August 16, 2024)	Subsidiary
46	Peerless Biotech Private Limited (w.e.f. August 16, 2024)	Subsidiary

